Etanercept combined with conventional treatment in Wegener's granulomatosis: A six-month open-label trial to evaluate safety

John H. Stone, Misty L. Uhlfelder, David B Hellmann, Sonya Crook, Nita Marie Bedocs, Gary S. Hoffman

Research output: Contribution to journalArticle


Objective. To evaluate the safety of etanercept (Enbrel) in patients receiving conventional treatment for Wegener's granulomatosis (WG). Methods. We performed a 6-month open-label trial of etanercept (25 mg subcutaneously twice weekly) which was added to standard therapies for WG (glucocorticoids, methotrexate, cyclophosphamide, azathioprine, cyclosporine) and prescribed according to disease severity. Evaluations of clinical response were determined by the Birmingham Vasculitis Activity Score for WG (BVAS/WG) in 20 patients with persistently active disease or with new flares of previously established WG. Fourteen of the 20 patients (70%) had etanercept added as the only new therapeutic variable. Results. Injection site reactions (ISRs) were the most common adverse event related to etanercept (8 episodes in 5 patients [25%];

Original languageEnglish (US)
Pages (from-to)1149-1154
Number of pages6
JournalArthritis and Rheumatism
Issue number5
Publication statusPublished - May 2001


ASJC Scopus subject areas

  • Immunology
  • Rheumatology

Cite this